Prediction model for SMM or worse may be used to defer bone marrow sampling in persons with MGUS

Using a trial of persons with monoclonal gammopathy of undetermined significance (MGUS), researchers developed a prediction model that accurately predicts the presence of 10 percent or more bone marrow plasma cells (BMPC) and therefore a diagnosis of smoldering multiple myeloma (SMM) or multiple myeloma (MM) by bone marrow criteria in persons presumed to have MGUS.

Moffitt Cancer Center Joins Dana-Farber Cancer Institute to Help Stop Blood Cancer

Moffitt Cancer Center has joined Dana-Farber Cancer Institute to provide free screenings to eligible adults who are at a higher risk for having or developing multiple myeloma or other related conditions. This initiative is through the PROMISE Study, a national cancer screening/cohort program to help researchers understand who is at risk based on a number of factors. The goal is to detect multiple myeloma before it becomes symptomatic and to monitor those who are at increased risk in order to study and hopefully prevent the development of the disease.